Steven Cohen Arcus Biosciences, Inc. Transaction History

Point72 Asset Management, L.P.

$39.3 Billion
Q1 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,914,932 shares of RCUS stock, worth $29.2 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

1,914,932

Previous 768,750 149.1%

Holding current value

$29.2 Million

Previous $14.7 Million 146.22%

% of portfolio

0.09%

Previous 0.04%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $17 Million - $23.1 Million	1,146,182 Added 149.1%	1,914,932 $36.2 Million
Q4 2023 Feb 14, 2024	BUY	$13.43 - $19.63 $10.3 Million - $15 Million	764,293 Added 17148.15%	768,750 $14.7 Million
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $12.4 Million - $16.6 Million	-705,184 Reduced 99.37%	4,457 $80,000
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $12 Million - $15.6 Million	709,641 New	709,641 $14.4 Million
Q1 2023 May 15, 2023	SELL	$15.96 - $23.15 $6.79 Million - $9.85 Million	-425,301 Closed	0 $0

Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $7.24 Million - $13.1 Million	367,467 Added 635.38%	425,301 $8.8 Million
Q3 2022 Nov 14, 2022	BUY	$23.23 - $30.07 $1.34 Million - $1.74 Million	57,834 New	57,834 $1.51 Million
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $1.43 Million - $2.25 Million	-62,926 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$26.16 - $41.39 $1.65 Million - $2.6 Million	62,926 New	62,926 $1.77 Million
Q4 2020 Feb 16, 2021	SELL	$17.0 - $32.36 $3.3 Million - $6.28 Million	-194,001 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$17.14 - $25.47 $3.33 Million - $4.94 Million	194,001 New	194,001 $3.33 Million

Others Institutions Holding RCUS

# of Institutions

186

Shares Held

49.2M

Call Options Held

204K

Put Options Held

149K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.1B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account